FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...

Keytruda works by inhibiting the activity of the programmed cell death protein 1 (PD-1), which typically limits the activity of your immune system. Cancer cells often produce PD-1 to prevent your ...

ImmunityBio Executive Chairman Patrick Soon-Shiong criticized the FDA for applying tougher approval standards to Anktiva than ...

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma. The combination ...

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Keytruda is proving effective in treating more and more types of cancer, and its long-term growth potential is massive in my view. I believe Keytruda is set to generate $31 billion revenue by the end ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...